Overview:

Summary

Global Markets Direct’s, 'Panic Disorders - Pipeline Review, Q2 2011', provides an overview of the Panic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Panic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Panic Disorders. 'Panic Disorders - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Panic Disorders.
- A review of the Panic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Panic Disorders pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Panic Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Panic Disorders pipeline depth and focus of Panic Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Panic Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Panic Disorders 7
Panic Disorders Therapeutics under Development by Companies 9
Panic Disorders Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Panic Disorders Therapeutics - Products under Development by Companies 14
Panic Disorders Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Panic Disorders Therapeutics Development 16
ZARS Pharma, Inc. 16
Abiogen Pharma S.p.A. 16
Panic Disorders - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Late Stage Drug Profiles 23
ABIO 08/01 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Alprazolam Patch - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
D-Cycloserine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Clonazepam + Sertraline - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Keppra - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Panic Disorders Therapeutics - Discontinued Products 30
Panic Disorders - Featured News 31
Mar 30, 2011: Bionomics Successfully Completes Two Phase Ib Clinical Trials Of BNC210 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 34
Contact Us 34
Disclaimer 34"

List of Tables
Number of Products Under Development for Panic Disorders, Q2 2011 7
Products under Development for Panic Disorders – Comparative Analysis, Q2 2011 8
Number of Products under Development by Companies, Q2 2011 9
Number of Products under Investigation by Universities/Institutes, Q2 2011 10
Comparative Analysis by Late Stage Development, Q2 2011 11
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 12
Comparative Analysis by Early Clinical Stage Development, Q2 2011 13
Products under Development by Companies, Q2 2011 14
Products under Investigation by Universities/Institutes, Q2 2011 15
ZARS Pharma, Inc., 2011 16
Abiogen Pharma S.p.A., 2011 16
Assessment by Monotherapy Products, Q2 2011 17
Assessment by Combination Products 18
Assessment by Stage and Route of Administration, Q2 2011 20
Assessment by Molecule Type, Q2 2011 22
Discontinued Products 30"

List of Figures
Number of Products under Development for Panic Disorders, Q2 2011 7
Products under Development for Panic Disorders – Comparative Analysis, Q2 2011 8
Products under Development by Companies, Q2 2011 9
Products under Investigation by  Universities/Institutes, Q2 2011 10
Late Stage Products, Q2 2011 11
Mid Clinical Stage Products, Q2 2011 12
Early Clinical Stage Products, Q2 2011 13
Assessment by Monotherapy Products, Q2 2011 17
Assessment by Combination Products, Q2 2011 18
Assessment by Route of Administration, Q2 2011 19
Assessment by Stage and Route of Administration, Q2 2011 20
Assessment by Molecule Type, Q2 2011 21
Assessment by Stage and Molecule Type, Q2 2011 22